Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non–Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&amp;CTONG1705)

Elsevier, Clinical Lung Cancer, 7(23), p. e395-e399, 2022

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non–Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)

Journal article published in 2022 by Si-Yang Maggie Liu

, Chang Lu, Xiao-Rong Dong, Yingying Du, Jiu-Wei Cui, Yuan Chen, Rui Ma, Bu-Hai Wang, Zhen Zhou, Shun-Dong Cang, Jin-Ji Yang, Hai-Yan Tu, Xu-Chao Zhang and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by